Developer of immersive therapeutics, including the prescription-use RelieVRx system for chronic lower-back pain.
Evidence and ecosystem, in one view.
Browse reviewed public metadata. Trust labels describe provenance—not clinical endorsement.
Catalog
Search by clinical need, modality, organization, or use case. Every result shows its source and review state.
A prescription-use immersive VR system providing adjunctive, skills-based treatment for adults with chronic lower-back pain.
FDA summary describing RelieVRx, its intended use, device classification, and relationship to the predicate device.
A 2025 article tracing development, authorization, and implementation considerations for a VR-delivered chronic lower-back-pain program.
Children undergoing short but painful procedures experience distress that sedation cannot always address, and fear compounds the pain itself.
In crises such as vaso-occlusive episodes, pain is severe and escalating analgesia carries its own risks, leaving a gap for non-pharmacological adjuncts.
Multi-week self-directed therapy works only if patients keep going after the first fortnight, and drop-off is the usual outcome.
Provider of a twelve-week chronic pain programme combining virtual reality with personalised behavioural coaching, aimed at restoring function.
Developer of biosensor-enabled VR environments for procedural and chronic pain, including a biofeedback experience driven by heart-rate monitoring.
Many VR studies measure change during or just after exposure. Evidence that effects persist weeks later, especially for chronic conditions, is thinner and inconsistent, which limits clinical and payer confidence.